Long-term safety and effectiveness of canakinumab therapy in patients with cryopyrin-associated periodic syndrome: results from the β-Confident Registry

OBJECTIVE: To report the long-term safety and effectiveness of canakinumab, a fully human anti-interleukin 1β monoclonal antibody, in patients with cryopyrin-associated periodic syndromes (CAPS), including familial cold autoinflammatory syndrome (FCAS), Muckle-Wells syndrome (MWS) and neonatal-onset...

Descripción completa

Detalles Bibliográficos
Autores principales: Walker, Ulrich A, Tilson, Hugh H, Hawkins, Philip N, van der Poll, Tom, Noviello, Stephanie, Levy, Jeremy, Vritzali, Eleni, Hoffman, Hal M, Kuemmerle-Deschner, Jasmin B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Autoinflammatory Disorders
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8130749/
https://www.ncbi.nlm.nih.gov/pubmed/34001647
http://dx.doi.org/10.1136/rmdopen-2021-001663

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8130749/
https://www.ncbi.nlm.nih.gov/pubmed/34001647
http://dx.doi.org/10.1136/rmdopen-2021-001663

Ejemplares similares